DoseMeRx
John Hardesky has over 19 years of experience in executive roles within the healthcare industry. John is currently the VP & CCO for DoseMeRx and was previously CCO for Nanomix from 2021 to 2023. Prior to that, they served as Head of Commercialization Services for LiquidSMARTS™ from 2020 to 2021 and as VP for Laboratory Solutions at McKesson from 2016 to 2020. John was also Vice President of Marketing for LABSCO from 2014 to 2016, and Chief Operating Officer for Vital Diagnostics, Inc. from 2005 to 2014. Earlier, they had a leadership role as President & CEO of Parke Diagnostics from 2004 to 2008, and as Vice President of Sales and Marketing for Polestar Labs from 2002 to 2004.
John Hardesky attended Lenoir-Rhyne University, but there is no information about when they started or when they finished, what degree they pursued, or what field of study they specialized in.
This person is not in any teams
This person is not in any offices
DoseMeRx
DoseMe is unique decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations and genotype to guide dose optimisation. It’s the world’s first precision dosing tool designed for clinical practice that uses Bayesian dosing methods. Its simplicity and portability means Bayesiandosing benefits can be brought to every bedside.